ArticlePharmaceutical research2026
Impact of Febrile State on Vancomycin Clearance in Pediatric Patients: Insights From Population Pharmacokinetic Modeling.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveAugmented renal clearance is increasingly recognized in pediatric patients with febrile neutropenia (FN), leading to enhanced elimination of renally cleared antimicrobials including vancomycin (VCM). Although fever‑associated hemodynamic changes may accelerate VCM clearance, their quantitative impact in the hospital-based general pediatric cohort remains unclear. The primary objective of this study was to quantify the effects of FN and infection-associated fever on VCM clearance in pediatric patients and to identify optimal dosing regimens across age and renal function strata.
methodsThis retrospective study included inpatients aged < 18 years receiving VCM with therapeutic drug monitoring. Population pharmacokinetic analysis was performed using a two‑compartment model with allometric scaling and maturation functions. Monte Carlo simulations were conducted to evaluate the probability of attaining a target area under the concentration-time curve (AUC
resultsA total of 129 patients and 214 VCM concentrations were analyzed. Estimated glomerular filtration rate and daily maximum body temperature (BT) ≥ 38°C were independently associated with increased VCM clearance. BT ≥ 38°C increased VCM clearance by 27%, and the final model showed robust predictive performance. Simulation analyses demonstrated that febrile patients required approximately 1.2-1.3‑fold higher daily VCM doses than those of afebrile patients across all age groups and renal function categories.
conclusionRenal function and BT ≥ 38°C significantly increase VCM clearance in pediatric patients. Standard dosing may be insufficient in febrile patients, and higher initial doses should be considered. Incorporating body temperature and renal function into dosing decisions may improve target exposure attainment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.